Clinical Trials Browser

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Phase 4 Not yet recruiting

100 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoid

Lymphoma, Recurrence

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

6 enrolled

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Lymphoid

Hodgkin Disease, Recurrence

NCT02686346 2021-12-07

BV-ICE

Phase 1/2 Completed

53 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT03474133 2020-07-21

BASALT

Phase 2 Unknown

80 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT03440788 2019-10-28

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

Unknown

70 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT02780011 2018-07-27

AD3LE

Phase 1 Withdrawn

Recurrence

NCT02280993 2018-03-13

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Phase 1 Unknown

72 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Phase NA Terminated

1 enrolled 5 charts

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Clinical Trials

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Bretuximab

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

EpiBrentlen

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

BV-ICE

BASALT

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

AD3LE

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30